CRISPR Therapeutics AG (NASDAQ: CRSP) on Friday, soared 6.77% from the previous trading day, before settling in for the closing price of $36.31. Within the past 52 weeks, CRSP’s price has moved between $30.04 and $67.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 31550.17% over the past five years. The company achieved an average annual earnings per share of -22.35%. With a float of $82.80 million, this company’s outstanding shares have now reached $86.36 million.
Let’s look at the performance matrix of the company that is accounted for 393 employees. In terms of profitability, gross margin is -259.34%, operating margin of -1313.44%, and the pretax margin is -1056.74%.
CRISPR Therapeutics AG (CRSP) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CRISPR Therapeutics AG is 4.13%, while institutional ownership is 67.69%. The most recent insider transaction that took place on Mar 21 ’25, was worth 413,578. In this transaction Chief Executive Officer of this company sold 10,031 shares at a rate of $41.23, taking the stock ownership to the 195,085 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Operating Officer sold 1,714 for $41.23, making the entire transaction worth $70,668. This insider now owns 10,544 shares in total.
CRISPR Therapeutics AG (CRSP) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -22.35% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
CRISPR Therapeutics AG (CRSP) is currently performing well based on its current performance indicators. A quick ratio of 15.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 88.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.52, a number that is poised to hit -1.36 in the next quarter and is forecasted to reach -4.35 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (NASDAQ: CRSP) saw its 5-day average volume 2.09 million, a negative change from its year-to-date volume of 2.18 million. As of the previous 9 days, the stock’s Stochastic %D was 65.14%. Additionally, its Average True Range was 2.23.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 33.78%, which indicates a significant decrease from 90.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.93% in the past 14 days, which was higher than the 63.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $38.04, while its 200-day Moving Average is $44.16. Nevertheless, the first resistance level for the watch stands at $39.60 in the near term. At $40.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $41.87. If the price goes on to break the first support level at $37.33, it is likely to go to the next support level at $35.88. The third support level lies at $35.06 if the price breaches the second support level.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
Market capitalization of the company is 3.35 billion based on 86,364K outstanding shares. Right now, sales total 37,310 K and income totals -366,250 K. The company made 870 K in profit during its latest quarter, and -136,000 K in sales during its previous quarter.